Community Health Systems, Inc. Announces Cash Tender Offers for up to $400.0 Million Aggregate Purchase Price of Its Outstanding Notes
Community Health Systems (CYH) has initiated cash tender offers to purchase up to $400 million of its outstanding debt, including 6.875% Senior Notes due 2022 and 8.125% Junior-Priority Secured Notes due 2024. The offers will prioritize the acceptance of the notes based on established levels, subject to proration. The early tender deadline is November 13, 2020, with an expected early settlement date of November 17, 2020. The company's intention is to utilize cash reserves for these purchases, alongside potential amendments to the restrictive covenants of the 2022 Notes.
- Initiation of cash tender offers up to $400 million, potentially lowering debt burden.
- Opportunity to amend restrictive covenants in the 2022 Notes, which might improve financial flexibility.
- Risk of proration may lead to incomplete acceptance of tendered notes.
- Potential impact on bondholders who do not consent to amendments could reduce the protections they have.
FRANKLIN, Tenn.--(BUSINESS WIRE)--Community Health Systems, Inc. (the “Company”) (NYSE: CYH) announced today that its wholly owned subsidiary, CHS/Community Health Systems, Inc. (the “Issuer”), has commenced tender offers (the “Tender Offers”) to purchase for cash its outstanding (i)
The complete terms and conditions of the Tender Offers and the Consent Solicitation (as defined below) are set forth in the Offer to Purchase that is being sent to holders of the Notes.
Subject to the Maximum Aggregate Purchase Price, the amount of a series of Notes that is purchased in the Tender Offers will be based on the order of priority (the “Acceptance Priority Level”) for such series of Notes as set forth in the table below, with 1 being the highest Acceptance Priority Level and 4 being the lowest Acceptance Priority Level, as further described in the Offer to Purchase. It is possible that the Issuer may not accept all Notes tendered under the Tender Offers. If the acceptance of all tenders in the Tender Offers would result in a maximum aggregate purchase price (excluding accrued and unpaid interest) that exceeds the Maximum Aggregate Purchase Price, tenders, other than with respect to the 2022 Notes validly tendered and not validly withdrawn at or prior to 5:00 p.m., New York City time, on November 13, 2020 (unless extended, the “Early Tender Deadline”), will be subject to proration arrangements as described in the Offer to Purchase.
The following table sets forth certain terms of the Tender Offers:
|
Dollars per |
|||||||||||
CUSIP No. |
Title of Security |
Aggregate
|
Acceptance
|
Total Offer
|
Early
|
Total
|
||||||
12543D AV2 |
|
|
1 |
|
|
|
||||||
12543D BA7 U17127AJ7 |
|
|
2 |
|
|
|
||||||
12543D AZ3 U17127AH1 |
Junior-Priority
|
|
3 |
|
|
|
||||||
12543D BE9 U17127AP3 |
|
|
4 |
|
|
|
(1) |
Aggregate principal amount outstanding for each series of Notes as of October 30, 2020. |
(2) |
Excludes accrued but unpaid interest, which will also be paid as provided in the Offer to Purchase. |
(3) |
Includes the Early Tender Payment. |
The consideration for each
As part of the Tender Offer relating to the 2022 Notes (the “2022 Tender Offer”), the Issuer is also soliciting consents (the “Consent Solicitation”) from the holders of the 2022 Notes for certain proposed amendments as set forth in the Offer to Purchase that would, among other things, eliminate substantially all restrictive covenants, certain events of default and certain other provisions contained in the indenture governing the 2022 Notes (the “Proposed Amendments”). Adoption of the Proposed Amendments with respect to the 2022 Notes requires the consent from at least a majority of the outstanding principal amount of 2022 Notes (the “Requisite Consent”). Each holder tendering 2022 Notes pursuant to the 2022 Tender Offer must also deliver a consent to the Proposed Amendments pursuant to the Consent Solicitation and will be deemed to have delivered their consents by virtue of such tender. Holders of the 2022 Notes may not deliver consents without also tendering their 2022 Notes. If the Proposed Amendments become operative with respect to the 2022 Notes, holders of the 2022 Notes that do not tender their 2022 Notes (or holders of the 2022 Notes whose tenders are not accepted, including because of any proration of the 2022 Notes tendered after the Early Tender Deadline) will be bound by the Proposed Amendments, meaning that the remaining outstanding 2022 Notes will no longer have the benefit of substantially all restrictive covenants and certain events of default contained in the 2022 Notes Indenture. In addition, such holders will not receive either the Tender Offer Consideration or the Early Tender Payment. The Issuer may, in its sole discretion, complete the 2022 Tender Offer even if valid consents sufficient to effect the Proposed Amendments are not received. If the 2022 Tender Offer is terminated, withdrawn or consummated without the Requisite Consents, the indenture governing the 2022 Notes will remain in effect in its present form.
The Issuer expects to use cash on hand to fund the Tender Offers and the Consent Solicitation, including fees (including the soliciting dealer fee described below) and expenses (including accrued and unpaid interest) payable in connection with the Tender Offers and the Consent Solicitation.
The Tender Offers and the Consent Solicitation are subject to the satisfaction or waiver of certain conditions as described in the Offer to Purchase. The Tender Offers are not conditioned upon the tender of any minimum principal amount of Notes (either of any series or in the aggregate), the consummation of any other Tender Offer or, in the case of the 2022 Tender Offer, obtaining the Requisite Consent. The Issuer expressly reserves the right for any reason, subject to applicable law, to extend, abandon, terminate or amend any Tender Offer and the Consent Solicitation.
The Issuer has agreed, upon the consummation of the 2022 Tender Offer, to pay a soliciting dealer fee equal to
The Issuer has retained Credit Suisse Securities (USA) LLC to act as the dealer manager in connection with the Tender Offers and as the solicitation agent in connection with the Consent Solicitation. Questions about the Tender Offers or the Consent Solicitation may be directed to Credit Suisse Securities (USA) LLC at (800) 820-1653 (toll free) or (212) 538-2147 (collect). Copies of the Offer to Purchase and other related documents may be obtained from Global Bondholder Services Corporation, the tender agent and the information agent for the Tender Offers and the Consent Solicitation, at (866) 470-3800 (toll free) or (212) 430-3774 (collect) or email contact@gbsc-usa.com.
This press release shall not constitute an offer to buy or sell, or the solicitation of any offer to buy or sell, any securities. Any offer or solicitation with respect to the Tender Offers will be made only by means of the Offer to Purchase, and the information in this press release is qualified by reference to the Offer to Purchase. The Tender Offers are not being made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. Holders must make their own decision as to whether to tender any of their Notes, and, if so, the principal amount of Notes to tender.
Forward-Looking Statements
This press release may include information that could constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risk and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law.